The estimated Net Worth of Kruif John De is at least $1.44 million dollars as of 12 August 2021. John De owns over 5,572 units of Merus N.V stock worth over $908,509 and over the last 5 years he sold MRUS stock worth over $0. In addition, he makes $531,790 as Chief Technology Officer at Merus N.V.
John has made over 15 trades of the Merus N.V stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,572 units of MRUS stock worth $280,160 on 12 August 2021.
The largest trade he's ever made was exercising 5,572 units of Merus N.V stock on 12 August 2021 worth over $280,160. On average, John trades about 463 units every 31 days since 2020. As of 12 August 2021 he still owns at least 18,069 units of Merus N.V stock.
You can see the complete history of John De stock trades at the bottom of the page.
Dr. John de Kruif Ph.D. serves as Chief Technology Officer of the Company. His responsibilities include management of antibody discovery, antibody platform technology development, antibody engineering, external collaborations, partnerships management and operational activities. Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr. de Kruif holds a PhD in Antibody Engineering from Utrecht University.
As the Chief Technology Officer of Merus N.V, the total compensation of John Kruif at Merus N.V is $531,790. There are 6 executives at Merus N.V getting paid more, with Hui Liu having the highest compensation of $1,382,530.
John Kruif is 56, he's been the Chief Technology Officer of Merus N.V since 2013. There are 6 older and 10 younger executives at Merus N.V. The oldest executive at Merus N.V is Gregory Perry, 59, who is the Independent Non-Executive Vice Chairman of the Board.
Kruif's mailing address filed with the SEC is C/O MERUS N.V., YALELAAN 62, UTRECHT, P7, 3584 CM.
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Merus N.V executives and other stock owners filed with the SEC include: